Skip to content

D&A at other companies

Emergent Biosolutions logo
Emergent BiosolutionsEBS
$23.5M-7.5%
Opko Health logo
Opko HealthOPK
$22.2M-5.5%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$439K-8.0%
Septerna, Inc. logo
Septerna, Inc.SEPN
$421K+6.0%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$408K+97.1%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$67.15M-44.2%

Other financials

Income statement

See full
Revenue$6.2M-11.3%
Gross profit$3.3M-52.0%
Operating income-$5.3M-136%
Net income-$3.5M-746%
EPS (diluted)-$0.05-400%

Balance sheet

See full
Cash & equivalents$145.6M-10.3%
Total debt$601.0K-50.6%
Total equity$151.6M-29.8%
Total assets$219.4M-11.2%

Cash flow

See full
Operating cash flow-$8.7M-223%
CapEx--100%
Free cash flow-$8.7M-223%

Valuation

See full
Market cap$261.08M-44.3%
Enterprise value$116.11M-59.6%
P/E10.3×+3.8×
P/S2.8×+0.2×

Profitability

See full
Gross margin65.4%-11.2pp
Operating margin52.4%-7.8pp
Net margin43.2%-6.1pp
FCF margin66.2%

Returns & leverage

See full
Return on equity39.9%-18.5pp
Debt / equity0.0×
Current ratio3.2×-5.2×

Where this comes from

Reported directly by SIGA Technologies in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: SIGA Technologies’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about SIGA Technologies's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SIGA Technologies's D&A?
SIGA Technologies (SIGA) reported D&A of $149.95K in Q1 2026.
How has SIGA Technologies's D&A changed year-over-year?
SIGA Technologies's D&A increased by 49.9% year-over-year, from $100K to $149.95K.
What is the long-term trend for SIGA Technologies's D&A?
Over 4 years (2021 to 2025), SIGA Technologies's D&A has grown at a 3.0% compound annual growth rate (CAGR), from $500K to $562.61K.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.